MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
KPV Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH), which retains the anti-inflammatory and antimicrobial activity of the parent hormone while lacking the melanocortin receptor pigmentary effects driven by the larger peptide. Proposed mechanisms include intracellular inhibition of NF-kB nuclear translocation downstream of IkB phosphorylation, suppression of TNF-alpha, IL-1 beta, and IL-6 production by activated macrophages, attenuation of mast cell degranulation, and direct antimicrobial activity against gram-positive bacteria and Candida species at micromolar concentrations. Researchers study KPV for inflammatory bowel disease using oral and intracolonic delivery in DSS and TNBS colitis models, atopic dermatitis, acne vulgaris, post-surgical wound healing, and chemotherapy-induced oral mucositis. Foundational work was performed by Brzoska, Luger, and Kannengiesser, with mechanistic detail in PMID 18486392 (Kannengiesser 2008) and PMID 18843151 (Brzoska 2008).
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen at −20 °C or below; reconstituted refrigerated at 2–8 °C; avoid repeated freeze–thaw.
Plasma half-life: Short in plasma due to rapid peptidase cleavage of the unmodified tripeptide; topical and oral encapsulated delivery formats are used in colitis and dermatology research to achieve tissue exposure.
Onset: Anti-inflammatory effects on cytokine profiles are detectable within hours in cellular assays; clinical signs in animal colitis models improve over 5 to 10 days of daily dosing.
Regulatory status: Not approved by FDA, EMA, or other major regulators. Research compound only; no large randomized human trials support inflammatory bowel disease or dermatology claims.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds.
Interactive KPV Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 6 units (0.06 mL) |
| Week 2 | 300 mcg | 9 units (0.09 mL) |
| Week 3 | 400 mcg | 12 units (0.12 mL) |
| Weeks 4–8 | 500 mcg | 15 units (0.15 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (KPV, 10 mg each):
- check8 weeks ≈ 3 vials
- check12 weeks ≈ 4 vials
- check16 weeks ≈ 6 vials
Insulin Syringes (U‑100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- check12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- check16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
KPV is the C-terminal tripeptide fragment Lys-Pro-Val of alpha-melanocyte-stimulating hormone (alpha-MSH), the 13-amino-acid peptide derived from proopiomelanocortin (POMC) that classically acts on the MC1R to drive melanin synthesis but also on MC1R, MC3R, MC4R, and MC5R in immune and central nervous system tissues to exert broad anti-inflammatory and immunomodulatory effects [1][2]. Most of the anti-inflammatory activity of alpha-MSH can be attributed to its C-terminal tripeptide KPV; however, KPV lacks the pigmentary effect of the full alpha-MSH molecule because it does not activate MC1R on melanocytes with sufficient potency to drive melanogenesis. This dissociation makes KPV particularly attractive for chronic anti-inflammatory applications where alpha-MSH-related hyperpigmentation would be unacceptable [2]. The mechanism of KPV anti-inflammatory action is multifaceted. KPV inhibits NF-kB nuclear translocation in macrophages, dendritic cells, T cells, and intestinal epithelial cells, suppressing transcription of TNF-alpha, IL-1beta, IL-6, IL-8, IFN-gamma, and other pro-inflammatory cytokines [1][2]. KPV also reduces leukocyte adhesion and migration into inflamed tissues by downregulating adhesion molecule expression on endothelium and chemokine release. In intestinal epithelial cells, KPV reduces oxidative stress and supports tight junction integrity in models of inflammatory bowel disease [3][4]. A key pharmacokinetic feature of KPV is its substrate specificity for PepT1, the proton-coupled di/tripeptide transporter normally expressed at low levels in small intestine but markedly upregulated in inflamed colonic epithelium during inflammatory bowel disease [3]. This means that oral KPV is selectively taken up by inflamed intestinal tissue, providing a form of disease-targeted drug delivery that does not require chemical modification of the peptide. In Dalmasso and Merlin's seminal studies, oral KPV in drinking water at 205 mcg/day reduced DSS-induced colitis severity, decreased histological inflammation scores, and suppressed pro-inflammatory cytokine production in the inflamed colon [3]. The plasma half-life of KPV is short (minutes), but the local tissue retention in inflamed mucosa is much longer because of PepT1-mediated uptake. Common research routes include oral capsules or compounded liquid (200 to 500 mcg/day), subcutaneous injection (200 to 500 mcg/day), and topical formulations for dermatologic research applications. Common research applications include inflammatory bowel disease (Crohn disease and ulcerative colitis), atopic dermatitis and contact dermatitis, mast cell activation syndrome and chronic urticaria, periodontal disease, and adjunctive use in regenerative protocols where suppression of inflammation supports healing. The combination of KPV with BPC-157, TB-500, and GHK-Cu (the four-peptide healing stack) is one of the most commonly cited unregulated research protocols in the regenerative space, with KPV providing the anti-inflammatory component complementing the angiogenic, migratory, and tissue-remodeling effects of the other peptides. KPV's distinct status as a non-pigmentary alpha-MSH fragment makes it preferred over full-length alpha-MSH or longer fragments for chronic use, particularly in patients with darker skin tones or those concerned about cosmetic pigmentary changes. As with other unregulated research peptides, the absence of large randomized double-blind placebo-controlled trials in any indication remains the principal limitation of the evidence base, and conclusions about clinical effectiveness should be interpreted cautiously.
Clinical Trial Efficacy Highlights
- starBrzoska, Luger, Maaser, Abels, and Bohm reviewed in Endocrine Reviews the comprehensive evidence that alpha-MSH and its tripeptide fragments including KPV exert potent anti-inflammatory and immunomodulatory effects across in vitro and in vivo models of immune-mediated disease [2].
- starDalmasso, Charrier-Hisamuddin, Nguyen, Yan, Sitaraman, and Merlin demonstrated in Gastroenterology that PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation in DSS-induced colitis, with oral KPV at 205 mcg/day in drinking water significantly reducing histological damage and cytokine release [3].
- starXiao, Saksena, Zhang, et al. showed that orally targeted delivery of KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviated ulcerative colitis in animal models, supporting both the underlying anti-inflammatory mechanism and innovative delivery strategies [4].
- starIn vitro studies in keratinocytes, dendritic cells, and T cells have shown that KPV inhibits NF-kB nuclear translocation, reduces TNF-alpha and IL-1beta release, and attenuates inflammatory dermatosis models in animals, providing the mechanistic basis for dermatologic research applications [5].
- starKPV has been shown in animal models of contact hypersensitivity to attenuate ear swelling and inflammatory infiltrate when applied topically, supporting research interest in atopic dermatitis and chronic eczema [2][5].
- starIn mast cell models, KPV reduces degranulation, histamine release, and pro-inflammatory cytokine production, providing rationale for exploratory use in mast cell activation syndrome and chronic urticaria [6].
- starAnti-microbial activity of KPV against Staphylococcus aureus, Candida albicans, and other organisms has been demonstrated in vitro, contributing to interest in wound healing applications where infection control is relevant [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningKPV has been broadly described as well tolerated in preclinical studies, with no serious adverse events attributable to the peptide in published animal studies and the limited human pilot data.
- warningInjection site reactions including mild erythema and transient discomfort are the most common adverse events with subcutaneous administration; oral dosing has been associated with rare mild gastrointestinal symptoms.
- warningUnlike alpha-MSH, KPV does not cause hyperpigmentation because it does not significantly activate MC1R on melanocytes; this is a key advantage for chronic use.
- warningTheoretical concerns include immunosuppression with prolonged high-dose use; KPV's anti-inflammatory mechanism could theoretically attenuate normal immune surveillance, although this has not been demonstrated in published studies.
- warningLong-term safety data are limited; published human exposure is restricted to short-term courses, and chronic dosing safety has not been characterized.
- warningUse in pregnancy, lactation, and pediatric populations has not been adequately studied and is not recommended.
- warningDrug-drug interactions have not been formally characterized; theoretical pharmacodynamic interactions with immunosuppressants and corticosteroids exist but have not been studied.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical KPV dosage?expand_more
Research protocols typically use 200 to 500 mcg/day, divided into one or two doses, given subcutaneously or orally. Oral dosing leverages PepT1-mediated uptake in inflamed intestine for IBD applications. Cycles of 4 to 8 weeks are common with longer-term use cycled rather than continuous.
How is KPV used in research protocols?expand_more
Primary applications include inflammatory bowel disease (Crohn disease, ulcerative colitis), atopic and contact dermatitis, mast cell activation syndrome, chronic urticaria, periodontal inflammation, and adjunctive use in regenerative healing protocols. Outcome measures include endoscopic and histologic scores, dermatologic severity scales, and validated symptom inventories.
Can KPV be combined with other peptides?expand_more
KPV is commonly stacked with BPC-157 and TB-500 in research healing protocols (the BPC-157 plus TB-500 plus KPV plus GHK-Cu combination is widely studied). KPV's anti-inflammatory effect complements the angiogenic and migratory effects of the other peptides.
What are the side effects of KPV?expand_more
Most users report only mild local reactions and occasional transient gastrointestinal symptoms with oral dosing. Unlike alpha-MSH, KPV does not cause hyperpigmentation. Theoretical concerns about immunosuppression with prolonged use exist but have not been confirmed clinically.
Is KPV FDA approved?expand_more
No. KPV is not approved by the FDA, EMA, or other major Western regulators for any indication. It is used only in research contexts. Compounded pharmacy availability in the United States has been restricted under FDA Section 503A regulations.
Academic References & Study Citations
Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29. View Scientific Paper →
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. View Scientific Paper →
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. View Scientific Paper →
Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. View Scientific Paper →
Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55. View Scientific Paper →
Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol. 2006;126(9):1966-1975. View Scientific Paper →
Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. View Scientific Paper →
Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610. View Scientific Paper →
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. View Scientific Paper →